International Journal on Science and Technology

E-ISSN: 2229-7677   •   Impact Factor: 9.88

A Widely Indexed Open Access Peer Reviewed Multidisciplinary Bi-monthly Scholarly International Journal

Call for Paper Volume 16 Issue 2 April-June 2025 Submit your research before last 3 days of June to publish your research paper in the issue of April-June.
Submit Research Paper Join as a Reviewer

Plagiarism is checked by the leading plagiarism checker TurnItIn

Call for Paper

Volume 16 Issue 2
2025

Submit your research paper

Indexing Partners
Academia Advanced Sciences Index Bielefeld Academic Search Engine CiteSeer DRJI Google Scholar Independent Search Engine & Directory Network ISI (International Scientific Indexing) Issuu Mendeley Research Networks
RefSeek ResearcherId - Thomson Reuters ResearchGate Scirus Scribd Semantic Scholar UTeM - Universiti Teknikal Malaysia Melaka Wiki for Call for Papers WorldCat Zenodo

Review of Immunotherapy in Bladder Cancer

Author(s) Chrysoula I. Liakou, Marios Papadakis
Country United States
Abstract The development of immunotherapy has become a groundbreaking therapeutic method to treat bladder cancer even though this malignancy frequently recurs and leads to significant complications. Recent progress in the knowledge on tumor microenvironment and mechanisms of immune escape gives rise to therapeutic strategies to strengthenanti-tumor immunity. Therapeutic strategies rely heavily on tumor-infiltrating lymphocytes (TILs) because research has shown that these immune cells play an essential role in the immunological response to bladder cancer. Studies reveal that TIL densities and their specific composition predict more favorable clinical results, making them ideal candidates for prognosis who could become therapy targets.
The blockade of immune checkpoint receptors CTLA-4 and PD-1/PD-L1 now shapes the current treatment approaches for bladder cancer patients. Such treatment methods intend to revive exhausted T cells, enabling them to generate strong tumor-targeting responses. The administration of anti-CTLA-4 medications in clinical trials produces two favorable outcomes: improved effector T cell numbers and augmented production of central cytokines including IFN-γ in tumorous and non-tumorous tissues. The modified immune scenario provides vital benefits to patients by improving their ability to defeat the immune-blocking tumor microenvironment.
Scientific researchers are currently testing combined delivery of immunotherapeutic treatments and conventional cancer therapies like chemotherapy and radiation to achieve the best outcomes. Multiple research studies in animals and human testing confirm that combining diverse immune therapeutic agents leads to complementary anti-tumor immune responses that benefit patient health. Standard bladder cancer treatment gained a new direction when immunotherapy became integrated into established protocols,providing increased patient survival possibilities and better overall health quality.
The successful implementation of immunotherapy to treat bladder cancer still faces various ongoing difficulties. Medical experts focus on unraveling three main challenges in bladder cancer treatment: unpredictable patient reactions, developing resistance to therapy, and identifying accurate prediction biomarkers. Research in the coming years should assess how the immune system interacts with bladder cancer, leading to better and patient-specific immunotherapy treatments.
Keywords Immunotherapy, Bladder Cancer, Tumor-Infiltrating Lymphocytes, Tils, Immune Evasion, Anti-Tumor Immunity, Checkpoint Blockade, CTLA-4, PD-1, PD-L1, Cytokines, IFN-Γ, Prognostic Biomarkers, Therapeutic Targets, Clinical Trials, Chemotherapy, Radiation, Treatment Landscape, Immunosuppressive Microenvironment, Effector T Cells, Resistance Mechanisms, Personalized Medicine, Combination Therapy, Patient Outcomes, Immune Response, Survival Rates, Quality Of Life, Ongoing Research, Immune System, Cancer Treatment
Field Medical / Pharmacy
Published In Volume 16, Issue 1, January-March 2025
Published On 2025-03-10
Cite This Review of Immunotherapy in Bladder Cancer - Chrysoula I. Liakou, Marios Papadakis - IJSAT Volume 16, Issue 1, January-March 2025. DOI 10.71097/IJSAT.v16.i1.2413
DOI https://doi.org/10.71097/IJSAT.v16.i1.2413
Short DOI https://doi.org/g87rg4
View / Download PDF File

Share this



CrossRef

CrossRef DOI is assigned to each research paper published in our journal.

IJSAT DOI prefix is
10.71097/IJSAT

Downloads
Research Paper Format Copyright Permission Form and Undertaking Form Cover Page Vol 15 Isu 4Cover Page Vol 15 Isu 3Cover Page Vol 15 Isu 2

All research papers published on this website are licensed under Creative Commons Attribution-ShareAlike 4.0 International License, and all rights belong to their respective authors/researchers.

CC-BY-SA Open Access

About IJSAT
Fees & Payment
Current Issue
Publication Archive 		Submit Research Paper
Track Submission Status
Publication Guidelines
Publication Ethics
Peer Review & Plagiarism 		Join as a Reviewer
Editors & Reviewers
Reviewer Referral Program
Get Reviewer Membership Certi. 		Website/Journal Policies
Usage Policy
Content Policies
Privacy Policy
Contact Us Message on WhatsApp +91-9687-182-185 editor@ijsat.org